FTSE MIB
34.249,77 +309,97 (+0,91%) Dow Jones
38.239,66 +153,86 (+0,40%) Nasdaq
15.927,90 +316,10 (+2,02%) Nikkei 225
37.934,76 +306,26 (+0,81%) Petrolio
83,66 +0,09 (+0,11%) Bitcoin EUR
59.552,25 +741,18 (+1,26%)
TEVA Jan 2025 12.000 call
| Chiusura precedente | 2,4800 |
| Aperto | 3,1500 |
| Denaro | 2,5600 |
| Lettera | 3,5000 |
| Prezzo d'esercizio | 12,00 |
| Scadenza | 2025-01-17 |
| Min-Max giorno | 3,1500 - 3,1500 |
| Contratto - Min-Max | N/D |
| Volume | |
| Open Interest | 11,51k |
GlobeNewswireTeva Pharmaceuticals and Alvotech Provide Update on Strategic Biosimilars Partnership
TEL AVIV, Israel and PARSIPPANY, N.J. and REYKJAVIK, Iceland, July 24, 2023 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), a global leader in generic and innovative medicines and Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that they have agreed to expand their existing strategic partnership agreement.
- GlobeNewswire
Alvotech and Teva Secure U.S. License Date for AVT04, a Proposed Biosimilar to Stelara®
According to the settlement agreement, AVT04 (ustekinumab) can be marketed in the US, subject to regulatory approval, no later than February 21, 2025 REYKJAVIK, Iceland and TEL AVIV, Israel and PARSIPPANY, N.J., June 12, 2023 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and Teva Pharmaceuticals, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA
